Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Common-Size Income Statement 

Allergan PLC, common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net revenues 100.00 100.00 100.00 100.00 100.00
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights -15.50 -13.88 -13.60 -12.77 -31.92
Gross profit 84.50% 86.12% 86.40% 87.23% 68.08%
Research and development -11.26 -14.35 -13.17 -17.68 -15.65
Selling and marketing -21.52 -20.59 -22.05 -22.42 -19.34
General and administrative -15.43 -8.05 -9.42 -10.12 -11.72
Amortization -36.40 -41.50 -45.15 -44.41 -36.18
Goodwill impairments -22.08 -18.00 0.00 0.00 0.00
In-process research and development impairments -2.71 -5.10 -9.11 -5.11 -3.39
Asset sales and impairments, net -2.74 -18.10 -24.64 -0.03 -1.80
Operating loss -27.63% -39.57% -37.15% -12.53% -20.00%
Interest income 0.48 0.29 0.42 0.48 0.08
Interest expense -4.87 -5.77 -6.87 -8.89 -7.92
Teva Share Activity 0.00 0.39 -20.51 0.00 0.00
Sale of businesses 0.00 1.16 0.00 0.00 0.00
Debt extinguishment costs as part of the debt tender offer 0.00 0.00 -1.01 0.00 0.00
Debt extinguishment other 0.00 0.10 -0.17 0.00 0.00
Other-than-temporary impairments 0.00 0.00 -0.16 0.00 0.00
Dividend income 0.00 0.00 0.53 0.47 0.00
Naurex recovery 0.00 0.00 0.13 0.00 0.00
Forward sale of Teva shares 0.00 0.00 -0.39 0.00 0.00
Pfizer termination fee, Allergan plc only 0.00 0.00 0.00 1.03 0.00
Bridge loan commitment fee 0.00 0.00 0.00 0.00 -1.76
Interest rate lock 0.00 0.00 0.00 0.00 0.21
Other 0.21 -0.02 0.03 0.01 0.00
Other income (expense), net 0.20% 1.63% -21.56% 1.50% -1.55%
Loss before income taxes and noncontrolling interest -31.82% -43.43% -65.16% -19.44% -29.40%
(Provision) benefit for income taxes -0.91 11.22 41.85 13.02 10.36
Net loss from continuing operations, net of tax -32.73% -32.22% -23.31% -6.42% -19.03%
Income (loss) from discontinued operations, net of tax 0.00 0.00 -2.53 109.22 45.04
Net income (loss) -32.73% -32.22% -25.84% 102.81% 26.01%
Income attributable to noncontrolling interest -0.04 -0.06 -0.04 -0.04 -0.03
Net income (loss) attributable to shareholders -32.76% -32.28% -25.88% 102.76% 25.98%
Dividends on preferred shares 0.00 -0.29 -1.75 -1.91 -1.54
Net income (loss) attributable to ordinary shareholders -32.76% -32.58% -27.63% 100.85% 24.44%

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Income statement item Description The company
Operating loss The net result for the period of deducting operating expenses from operating revenues. Allergan PLC operating loss as a percentage of net revenues decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Loss before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC loss before income taxes and noncontrolling interest as a percentage of net revenues increased from 2017 to 2018 and from 2018 to 2019.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC net income (loss) attributable to shareholders as a percentage of net revenues decreased from 2017 to 2018 and from 2018 to 2019.